- Home
- NKTX vs FENC Comparison
NKTX vs FENC Comparison
Compare NKTX & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NKTX | FENC |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 230.8M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NKTX | FENC |
|---|---|---|
| Price | $2.60 | $9.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $11.33 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 488.9K | 258.0K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.88 | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $896.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.63 | $5.65 |
| 52 Week High | $3.65 | $10.45 |
Technical Indicators
Market Signals| Indicator | NKTX | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 54.05 |
| Support Level | $2.59 | $7.40 |
| Resistance Level | $2.78 | $9.15 |
| Average True Range (ATR) | 0.22 | 0.49 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 28.57 | 33.12 |
Price Performance
Historical ComparisonAbout NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.